Comparison of the National Genetics Institute (NGI) HCV Superquant and Roche COBAS Amplicor HCV Monitor, Version 2.0 Assays

Update item information
Publication Type Poster
School or College School of Medicine
Department Pathology
Program ARUP Institute for Clinical and Experimental Pathology
Creator Konnick, Eric Q.; Erali, Maria; Ashwood, Edward R.; Hillyard, David R.
Title Comparison of the National Genetics Institute (NGI) HCV Superquant and Roche COBAS Amplicor HCV Monitor, Version 2.0 Assays
Date 2000-04-22
Description Chronic Hepatitis C infection is currently recognized as an important health care problem. It is estimated that nearly 4 million Americans are infected, 15 to 20 percent of whom will eventually develop Cirrhosis. Current treatments for Hepatitis C virus (HCV) are limited to alfa-interferon alone or in combination therapy with Ribavirin. Quantitation of HCV RNA in patient samples has become a valuable tool in the evaluation of patients undergoing therapy and has been used as a measure of response to treatment. Three recent studies (Poynard, Davis, McHutchinson) investigating the effectiveness of alfa-interferon and Ribavirin therapy have used HCV RNA viral loads as a marker for treatment efficacy.
Type Text
Publisher University of Utah
Subject Cirrhosis; Patients
Subject MESH Hepatitis C, Chronic; Therapeutics; Ribavirin
Language eng
Bibliographic Citation Konnick EQ, Erali M, Ashwood ER, Hillyard DR. Comparison of the National Genetics Institute (NGI) HCV Superquant and Roche COBAS Amplicor HCV Monitor, Version 2.0 Assays.
Format Medium application/pdf
Identifier ir-main,498
ARK ark:/87278/s6q81xkz
Setname ir_uspace
Date Created 2012-06-13
Date Modified 2012-06-13
ID 705754
Reference URL https://collections.lib.utah.edu/ark:/87278/s6q81xkz
Back to Search Results